18-01-2020

18-01-2020

37 D. Rimm - Analytic approaches to understanding PD-L1 expression and mechanism of action.

37 D. Rimm - Analytic approaches to understanding PD-L1 expr...

38 N. Normanno - Liquid biopsies: facts and myths.

38 N. Normanno - Liquid biopsies: facts and myths.

39 F. Hirsch - Next Generation Sequencing: is there any clinical use?

39 F. Hirsch - Next Generation Sequencing: is there any clin...

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKIs.

40 G. Bronte - Mechanisms of acquired resistance to EGFR TKI...

41 Discussion

42 L. Landi - Current treatment algorithms for EGFR-mutated patients.

42 L. Landi - Current treatment algorithms for EGFR-mutated...

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ patients.

43 B. Oyan-Uluc - Current treatment algorithms for ROS1+ pat...

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, ALK and ROS1.

44 V. Papadimitrakopoulou - Targeted therapy beyond EGFR, AL...

45 Discussion

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

46 E. Linardou - Lorlatinib in ALK+ NSCLC: the next step.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials to practice.

47 S. Agelaki - Immunotherapy in 1st line NSCLC: from trials...

48 F. Grossi - I O combination in 1st line NSCLC - practice changing?

48 F. Grossi - I O combination in 1st line NSCLC - practice...

49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.

49 S. Gettinger - Immunotherapy in oncogene driven mNSCLC.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

50 D. Rimm - Immunotherapy biomarkers beyond PD-L1.

51 R. Pirker - The role of targeted therapies in early stages of NSCLC.

51 R. Pirker - The role of targeted therapies in early stage...

2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white